

David S Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6326936/publications.pdf>

Version: 2024-02-01

258
papers

9,443
citations

47409

49
h-index

53065

89
g-index

268
all docs

268
docs citations

268
times ranked

8712
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors associated with 30-day postoperative complications following contemporary vulvectomies with inguofemoral lymphadenectomies for gynecologic cancers. <i>Gynecologic Oncology</i> , 2022, 164, 2-3.	0.6	0
2	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 968-977.	0.8	38
3	A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. <i>Gynecologic Oncology</i> , 2022, 164, 481-491.	0.6	19
4	Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. <i>Gynecologic Oncology</i> , 2022, 164, 428-436.	0.6	5
5	Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 437-448.	13.9	375
6	Stage IVA cervical cancer: outcomes of disease related complications and treatment. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 518-523.	1.2	5
7	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 191-226.	2.3	356
8	Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 719-726.	1.1	6
9	Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors. <i>Journal of Pathology</i> , 2021, 254, 20-30.	2.1	9
10	Lynch Syndrome Identification in Endometrial Cancer Patients: Should Universal Screening be Used for all Histologies?. <i>Current Women's Health Reviews</i> , 2021, 17, .	0.1	0
11	Stigma, beliefs and perceptions regarding prostate cancer among Black and Latino men and women. <i>BMC Public Health</i> , 2021, 21, 758.	1.2	8
12	Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5563-5563.	0.8	3
13	Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5570-5570.	0.8	9
14	Is there a need for consultant team for bowel resection? An evaluation of surgical outcomes of bowel resection at time of ovarian cytoreductive surgery. <i>Gynecologic Oncology</i> , 2021, 162, S193.	0.6	0
15	Delayed time to surgery with hormonal treatment does not adversely impact outcomes in women with low-grade endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, S124.	0.6	0
16	Prognostic factors associated with overall survival in presumed early stage, high-grade serous ovarian cancer: an analysis of the SEER cancer database. <i>Gynecologic Oncology</i> , 2021, 162, S246.	0.6	1
17	A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, S4.	0.6	27
18	Risk factors associated with 30-day postoperative complications following contemporary pelvic exenterations for gynecologic cancer. <i>Gynecologic Oncology</i> , 2021, 162, S264-S265.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Perioperative risk factors and postoperative outcomes following pelvic exenterations for gynecologic versus non-gynecologic malignancies. <i>Gynecologic Oncology</i> , 2021, 162, S233-S234.	0.6	0
20	Stoma creation at the time of large bowel resection during ovarian cytoreductive surgery does not improve 30-day postoperative surgical outcomes. <i>Gynecologic Oncology</i> , 2021, 162, S278-S279.	0.6	0
21	Beyond Sedlisâ€”A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. <i>Gynecologic Oncology</i> , 2021, 162, 532-538.	0.6	22
22	726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physicianâ€™s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). <i>Annals of Oncology</i> , 2021, 32, S729-S730.	0.6	18
23	145â€”Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775). , 2021, , .		2
24	O002/#43â€”Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors. , 2021, , .		1
25	O008/#785â€”A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physicianâ€™s choice in patients with advanced endometrial cancer: study 309/keynote-775. , 2021, , .		6
26	A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 464-471.	0.4	66
27	Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2020, 156, 423-429.	0.6	23
28	Comparing overall survival in women diagnosed and treated for a gynecological sarcoma at a private versus county hospital. <i>Gynecologic Oncology</i> , 2020, 159, 247-248.	0.6	0
29	Association between elapsed time after initial diagnosis and outcomes in patients diagnosed with early stage cervical cancer at a safety net hospital. <i>Gynecologic Oncology</i> , 2020, 159, e9-e10.	0.6	0
30	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). <i>Journal of Clinical Oncology</i> , 2020, 38, 3841-3850.	0.8	155
31	Current practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: An SGO survey. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100620.	0.3	3
32	Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100627.	0.3	7
33	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1050-1060.	2.1	34
34	Practice patterns using minimally invasive surgery for the treatment of ovarian cancer: A survey of physician members of the Society of Gynecologic Oncologists. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100617.	0.3	4
35	An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. <i>Gynecologic Oncology</i> , 2020, 158, 354-360.	0.6	17
36	Second-line lenvatinib in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 575-582.	0.6	53

#	ARTICLE	IF	CITATIONS
37	Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2020, 157, 312-322.	0.6	6
38	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 178-188.	0.4	60
39	A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 18-18.	0.8	16
40	Beyond Sedlis: A novel, histology-based nomogram for predicting recurrence risk and need for adjuvant radiation in cervical cancerâ€”A NRG/GOG ancillary analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6019-6019.	0.8	0
41	Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18046-e18046.	0.8	0
42	125â€¦Results of a randomized phase ii trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent chemo-naïve stromal ovarian tumors. , 2020, , .		0
43	Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (â‰¥4th line), advanced, recurrent high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 3.	0.6	6
44	Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2317-2326.	13.9	326
45	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	5.1	68
46	The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. <i>Gynecologic Oncology</i> , 2019, 154, 13-21.	0.6	8
47	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1810-1818.	0.8	229
48	Reply to F. Tomao et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 936-936.	0.8	0
49	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 636-648.	5.1	366
50	Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 533-542.	0.9	25
51	A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naïve patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5500-5500.	0.8	29
52	A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5607-TPS5607.	0.8	9
53	Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5509-5509.	0.8	0
54	Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED â‰¥3 PRIOR CHEMOTHERAPY REGIMENS. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
55	Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1137-1141.	0.6	3
56	Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma Among a Multi-Institutional Academic Collaboration. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1220-1224.	0.6	6
57	Preoperative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 1020-1028.	0.8	30
58	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111.	0.5	15
59	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	0.8	21
60	Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 797-801.	0.6	3
61	Adenocarcinoma of the Uterine Corpus. , 2018, , 121-154.e8.		1
62	Locally Advanced Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 447-451.	0.6	6
63	Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 792-796.	0.6	8
64	Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. <i>International Journal of Cancer</i> , 2018, 142, 1102-1115.	2.3	21
65	Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 933-937.	0.6	9
66	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 174-180.	0.6	83
67	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	0.8	61
68	QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. <i>Annals of Oncology</i> , 2018, 29, viii337.	0.6	4
69	The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1225-1230.	0.6	15
70	GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study. <i>Gynecologic Oncology</i> , 2018, 149, 2.	0.6	19
71	Screening for Lynch syndrome in a medically underserved population. <i>Gynecologic Oncology</i> , 2018, 149, 143.	0.6	1
72	ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5503-5503.	0.8	25

#	ARTICLE	IF	CITATIONS
73	Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.. Journal of Clinical Oncology, 2018, 36, 5505-5505.	0.8	5
74	QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.. Journal of Clinical Oncology, 2018, 36, 5514-5514.	0.8	19
75	Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, locally advanced endometrial carcinoma: A Gynecologic Oncology Group/NRG study.. Journal of Clinical Oncology, 2018, 36, 5589-5589.	0.8	4
76	The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. Gynecologic Oncology, 2017, 144, 586-591.	0.6	10
77	Sparse feature selection for classification and prediction of metastasis in endometrial cancer. BMC Genomics, 2017, 18, 233.	1.2	19
78	A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study. Gynecologic Oncology, 2017, 145, 219.	0.6	15
79	Long-Term Percutaneous Nephrostomy Management of Malignant Urinary Obstruction: Estimation of Optimal Exchange Frequency and Estimation of the Financial Impact of Patient Compliance. Journal of Vascular and Interventional Radiology, 2017, 28, 1036-1042.e8.	0.2	19
80	Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecologic Oncology, 2017, 145, 519-525.	0.6	52
81	Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery. Cancer, 2017, 123, 192-196.	2.0	4
82	Response to "Towards implementation of sexual healthcare". Gynecologic Oncology Reports, 2017, 20, 139.	0.3	0
83	Weekly paclitaxel for recurrent ovarian cancer: Does weekly administration during primary therapy impact efficacy and toxicity at recurrence?. Gynecologic Oncology, 2017, 145, 155.	0.6	0
84	Description of Medium- and Long-Term Complications After PCN Placement for Malignant Urinary Obstruction [1J]. Obstetrics and Gynecology, 2017, 129, 103S-103S.	1.2	0
85	Considering Closed Incision Negative Pressure Therapy for Obese Patients with Gynecologic Malignancies [31E]. Obstetrics and Gynecology, 2017, 129, 59S-60S.	1.2	0
86	Determination of Optimal Routine Exchange Frequency After PCN Placement for Malignant Urinary Obstruction [35E]. Obstetrics and Gynecology, 2017, 129, 60S-61S.	1.2	0
87	A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1313.	0.4	38
88	Detection of Chronic Hepatitis B in Gynecologic Oncology Patients Undergoing Systemic Chemotherapy. Gynecologic Oncology, 2017, 147, 207-208.	0.6	0
89	Family History of Cancer Shows Improved Survival in Uterine Papillary Serous Carcinoma. Gynecologic Oncology, 2017, 147, 225-226.	0.6	0
90	Patients with Sarcopenia Benefit from Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. Gynecologic Oncology, 2017, 147, 226.	0.6	0

#	ARTICLE	IF	CITATIONS
91	New therapies for advanced, recurrent, and metastatic endometrial cancers. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 19.	3.6	72
92	A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5505-5505.	0.8	58
93	Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. <i>Obstetrics and Gynecology</i> , 2016, 128, 535-542.	1.2	58
94	Factors influencing primary treatment of midline vulvar cancers. <i>Gynecologic Oncology</i> , 2016, 142, 133-138.	0.6	0
95	Core muscle index is prognostic of survival in advanced ovarian cancers. <i>Gynecologic Oncology</i> , 2016, 143, 206-207.	0.6	1
96	Weekly Paclitaxel for Recurrent Ovarian Cancer: Does Weekly Administration at Primary Diagnosis Impact Efficacy and Toxicity at Recurrence?. <i>Gynecologic Oncology</i> , 2016, 143, 204.	0.6	0
97	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. <i>Gynecologic Oncology</i> , 2016, 143, 294-301.	0.6	31
98	The Opinions and Practices of Providers Toward the Sexual Issues of Cervical Cancer Patients Undergoing Treatment. <i>Gynecologic Oncology</i> , 2016, 143, 211-212.	0.6	0
99	Prognostic Significance of Nodal Location in Stage IIIC Endometrial Carcinoma: Implications for Optimal Adjuvant Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E303.	0.4	0
100	Sparse Feature Selection for Classification and Prediction of Metastasis in Endometrial Cancer. , 2016, , .		0
101	The Significance of Macrocephaly or Enlarging Head Circumference in Infants With the Triad. <i>American Journal of Forensic Medicine and Pathology</i> , 2015, 36, 111-120.	0.4	18
102	Defining optimal management of midline vulvar cancers. <i>Gynecologic Oncology</i> , 2015, 139, 179.	0.6	0
103	Emphasis on systemic therapy for women with pelvic bone involvement at time of diagnosis of cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 200.	0.6	0
104	Reply to W.A.A. Tjalma and J.S. Grossman. <i>Journal of Clinical Oncology</i> , 2015, 33, 966-966.	0.8	3
105	Ovarian involvement in endometrioid adenocarcinoma of uterus. <i>Gynecologic Oncology</i> , 2015, 138, 532-535.	0.6	32
106	Adjuvant External Radiation is Essential in the Management of Pelvis-Limited Stage III Endometrial Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, S10-S11.	0.4	0
107	Locally advanced cervical cancer: Effect of radiation dosage and treatment duration on outcomes. <i>Gynecologic Oncology</i> , 2015, 139, 179-180.	0.6	0
108	Anti-angiogenic treatment of cervical cancer significantly decreases new target lesions. <i>Gynecologic Oncology</i> , 2015, 139, 196.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Surgical and systemic management of endometrial cancer: an international survey. Archives of Gynecology and Obstetrics, 2015, 291, 897-905.	0.8	34
110	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. Journal of Clinical Investigation, 2015, 125, 4063-4076.	3.9	79
111	A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2014, 135, 441-445.	0.6	69
112	Malignant ovarian germ cell tumor " Role of surgical staging and gonadal dysgenesis. Gynecologic Oncology, 2014, 134, 84-89.	0.6	33
113	Distinct microscopic features of perineural invasion in adenoid cystic carcinoma of the head and neck. Histopathology, 2014, 64, 1037-1039.	1.6	13
114	Cervical cancer " Distant failure after treatment of para-aortic lymph node metastases. Gynecologic Oncology, 2014, 135, 389.	0.6	0
115	Isolated ovarian metastasis in endometrial adenocarcinoma of uterus. Gynecologic Oncology, 2014, 135, 393.	0.6	0
116	2A phase II study to determine the response to second curettage as initial management for persistent "low-risk" non-metastatic gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology, 2014, 134, 438-439.	0.6	9
117	Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group. Journal of Clinical Oncology, 2014, 32, 2744-2749.	0.8	16
118	The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncology, 2014, 4, 137-144.	1.1	151
119	Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecologic Oncology, 2014, 134, 552-555.	0.6	4
120	Factors associated with clinical trial screening failures in gynecologic oncology. Gynecologic Oncology, 2014, 134, 450-454.	0.6	7
121	Outcomes of phenotypic females with dysgerminoma and 46, XY karyotype. Gynecologic Oncology, 2013, 131, 257.	0.6	0
122	Survival Outcomes of Clinical Trials in Patients With Recurrent Cervical Cancer. Clinical Ovarian and Other Gynecologic Cancer, 2013, 6, 42-45.	0.1	1
123	Brachial Plexus Palsy and Shoulder Dystocia: Obstetric Risk Factors Remain Elusive. American Journal of Perinatology, 2013, 30, 303-308.	0.6	33
124	A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiotensin-2 as a predictive marker for clinical outcomes. Journal of Clinical Oncology, 2013, 31, 5520-5520.	0.8	37
125	Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review. Modern Chemotherapy, 2013, 02, 19-32.	0.5	6
126	Adenocarcinoma of the Uterine Corpus. , 2012, , 141-174.e6.		11

#	ARTICLE	IF	CITATIONS
127	Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. <i>Gynecologic Oncology</i> , 2012, 127, 43-46.	0.6	14
128	Stage IIIC1 versus IIIC2 endometrial adenocarcinoma of the uterus: Analysis of recurrence and patterns of toxicity. <i>Gynecologic Oncology</i> , 2012, 127, S18-S19.	0.6	0
129	Clinical course of ovarian cancer after two salvage regimens. <i>Gynecologic Oncology</i> , 2012, 127, S27-S28.	0.6	0
130	Survival outcomes after recurrence in endometrioid compared to papillary serous/clear cell carcinoma of the uterus. <i>Gynecologic Oncology</i> , 2012, 127, S28.	0.6	2
131	Incidence of adnexal metastasis requiring surgical intervention in women with advanced cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, S33.	0.6	0
132	A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 127, 456-461.	0.6	40
133	Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma?. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 242.e1-242.e5.	0.7	31
134	Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. <i>Gynecologic Oncology</i> , 2012, 124, 508-511.	0.6	4
135	Challenging prognostic factors for chemotherapy resistance in gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2012, 125, S84.	0.6	0
136	Effect of BMI on progesterone therapy for endometrial cancer. <i>Gynecologic Oncology</i> , 2012, 125, S163.	0.6	0
137	Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 125, 771.	0.6	214
138	Clinical Evidence: Metastases can Metastasize. <i>World Journal of Oncology</i> , 2012, 3, 138-141.	0.6	3
139	How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5087-5087.	0.8	0
140	Recurrence patterns in patients with stage IIIC1 versus IIIC2 endometrial adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15501-e15501.	0.8	0
141	PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 106-110.	0.2	0
142	A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011, 121, 118-121.	0.6	39
143	Outcomes of third line chemotherapy for recurrent and persistent cervical cancer. <i>Gynecologic Oncology</i> , 2011, 123, 442-443.	0.6	0
144	Predictive value of carcinoembryonic antigen and cancer antigen 125 in identifying mucinous ovarian tumors. <i>Gynecologic Oncology</i> , 2011, 123, 445-446.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Survival impact of clinical trials in patients with recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2011, 123, 447-448.	0.6	0
146	Challenging prognostic factors for chemotherapy resistance in high-risk gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2011, 123, 449.	0.6	0
147	Does myometrial invasion confer a poorer prognosis in uterine adenosarcoma?. <i>Gynecologic Oncology</i> , 2011, 123, 450.	0.6	0
148	The Role of Lymphadenectomy in Endometrial Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 235-244.	0.6	28
149	Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 825-831.	0.8	139
150	A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) women with locally advanced cervical cancer (CXCA): A GOG study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 5032-5032.	0.8	2
151	Third-line salvage chemotherapy for recurrent cervical cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, e15510-e15510.	0.8	0
152	Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. <i>Gynecologic Oncology</i> , 2010, 117, 239-247.	0.6	37
153	Should All Patients with Serous and Clear Cell Endometrial Carcinoma Receive Adjuvant Chemotherapy?. <i>Women's Health</i> , 2010, 6, 789-795.	0.7	4
154	PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2010, 3, 74-78.	0.2	0
155	A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1137-1141.	1.2	15
156	The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.. <i>Journal of Clinical Oncology</i> , 2010, 28, 5122-5122.	0.8	0
157	Pharmacotherapy of endometrial cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1939-1951.	0.9	18
158	Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 2686-2691.	0.8	163
159	Epigenetic Repression of <i>microRNA-129-2</i> Leads to Overexpression of <i>SOX4</i> Oncogene in Endometrial Cancer. <i>Cancer Research</i> , 2009, 69, 9038-9046.	0.4	262
160	A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology. <i>Gynecologic Oncology</i> , 2009, 115, 443-446.	0.6	34
161	Recent Progress: Gynecologic Oncology Group Trials in Uterine Corpus Tumors. <i>Reviews on Recent Clinical Trials</i> , 2009, 4, 70-74.	0.4	1
162	Chemo- and Radiotherapy in Adjuvant Management of Optimally Debulked Endometrial Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 535-541.	2.3	4

#	ARTICLE	IF	CITATIONS
163	Somatic LKB1 Mutations Promote Cervical Cancer Progression. PLoS ONE, 2009, 4, e5137.	1.1	229
164	Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecologic Oncology, 2008, 109, 411-417.	0.6	38
165	Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecologic Oncology, 2008, 110, 65-70.	0.6	55
166	Gynecologic oncology group trials in uterine corpus malignancies: recent progress. Journal of Gynecologic Oncology, 2008, 19, 218.	1.0	17
167	A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group. Journal of Clinical Oncology, 2008, 26, 5524-5524.	0.8	10
168	Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells. Reproductive Sciences, 2007, 14, 20-28.	1.1	37
169	Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. Gynecologic Oncology, 2007, 107, 316-319.	0.6	39
170	Secreted protein rich and acidic in cysteine (SPARC) as a predictor of cervical carcinogenesis and regulator of cervical cancer growth. Gynecologic Oncology, 2007, 107, 361-362.	0.6	0
171	Multi-institutional retrospective analysis of lymphadenectomy in early stage adenocarcinoma of the cervix. Gynecologic Oncology, 2007, 107, 366-367.	0.6	0
172	Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. American Journal of Obstetrics and Gynecology, 2006, 194, e20-e22.	0.7	11
173	Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, Tj ETQq1 1 0.784314 rgBT /Overlock 11). Gynecologic Oncology, 2006, 100, 537-543.	0.6	36
174	Gestational trophoblastic disease among Hispanic women: A 21-year hospital-based study. Gynecologic Oncology, 2006, 103, 81-86.	0.6	51
175	Advanced endometrial cancer: Is lymphadenectomy necessary or sufficient?. Gynecologic Oncology, 2006, 101, 191-193.	0.6	8
176	Hormonal therapy in epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2006, 6, 43-47.	1.1	17
177	Fertility-Sparing Surgery for Ovarian Low Malignant Potential Tumors. Obstetrical and Gynecological Survey, 2005, 60, 797-798.	0.2	0
178	Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas. Obstetrics and Gynecology, 2005, 106, 1304-1308.	1.2	94
179	Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles. American Journal of Obstetrics and Gynecology, 2005, 192, 1362-1364.	0.7	28
180	Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology, 2005, 96, 67-71.	0.6	19

#	ARTICLE	IF	CITATIONS
181	Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6â€“12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2005, 96, 810-817.	0.6	15
182	Fertility-sparing surgery for ovarian low malignant potential tumors. <i>Gynecologic Oncology</i> , 2005, 98, 263-266.	0.6	50
183	Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2005, 98, 217-221.	0.6	58
184	Clinical applications of hormonal therapy in ovarian cancer. <i>Current Treatment Options in Oncology</i> , 2005, 6, 97-102.	1.3	6
185	Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 4626-4633.	0.8	484
186	Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 3474-3478.	3.2	85
187	Understanding the Mechanisms of FHIT Inactivation in Cervical Cancer for Biomarker Development. <i>Journal of the Society for Gynecologic Investigation</i> , 2004, 11, 329-337.	1.9	10
188	Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2004, 92, 639-643.	0.6	53
189	Oral dexamethasone attenuates DoxilÂ®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. <i>Gynecologic Oncology</i> , 2004, 94, 320-324.	0.6	55
190	Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 674-679.	0.7	47
191	P16 as a molecular biomarker of cervical adenocarcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 668-673.	0.7	49
192	Other primary malignancies in patients with uterine corpus malignancy. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 1429-1431.	0.7	6
193	A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. <i>Cancer</i> , 2004, 100, 859-868.	2.0	51
194	Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 3113-3119.	0.8	520
195	Postmolar surveillance at a trophoblastic disease center that serves indigent women. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 1151-1153.	0.7	17
196	Cervical adenocarcinoma survival among Hispanic and white women: A multicenter cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 640-644.	0.7	9
197	Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. <i>Gynecologic Oncology</i> , 2003, 91, 558-562.	0.6	54
198	Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma. <i>Cancer</i> , 2003, 98, 1664-1669.	2.0	21

#	ARTICLE	IF	CITATIONS
199	Localized Retroperitoneal Lymphangiomyomatosis Mimicking Malignancy. Archives of Pathology and Laboratory Medicine, 2003, 127, 879-882.	1.2	35
200	Management of Low-Risk Gestational Trophoblastic Tumors in an Indigent Population. Obstetrics and Gynecology, 2002, 99, 92S.	1.2	0
201	Urinary Bladder Cancer. Clinical Obstetrics and Gynecology, 2002, 45, 844-854.	0.6	9
202	Stage IIBâ€“IVB Cervical Adenocarcinoma: Prognostic Factors and Survival. Gynecologic Oncology, 2002, 84, 115-119.	0.6	58
203	Early-Stage Cervical Adenocarcinoma Treated by Surgical Intent: The Role of Para-aortic Lymph Node Dissection. Gynecologic Oncology, 2002, 84, 285-288.	0.6	13
204	Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study. Gynecologic Oncology, 2002, 85, 507-510.	0.6	41
205	Endocervical Curettage at Conization to Predict Residual Cervical Adenocarcinoma in Situ. Gynecologic Oncology, 2002, 87, 129-132.	0.6	56
206	A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology, 2002, 87, 247-251.	0.6	86
207	Germline BRCA1â€“2 Mutations in Non-Ashkenazi Families with Double Primary Breast and Ovarian Cancer. Gynecologic Oncology, 2001, 83, 383-387.	0.6	8
208	Adenomyofibroma of the Endometrium with Skeletal Muscle Differentiation. International Journal of Gynecological Pathology, 2000, 19, 280-283.	0.9	15
209	Endometrial Endometrioid Carcinomas Associated with Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. International Journal of Gynecological Pathology, 2000, 19, 127-132.	0.9	37
210	Bacteriology and Treatment of Malodorous Lower Reproductive Tract in Gynecologic Cancer Patients. Obstetrics and Gynecology, 2000, 96, 23-27.	1.2	0
211	Uterine Metastasis from a Heterologous Metaplastic Breast Carcinoma Simulating a Primary Uterine Malignancy. Gynecologic Oncology, 2000, 77, 216-218.	0.6	11
212	Chromosome 4 Deletions Are Frequent in Invasive Cervical Cancer and Differ between Histologic Variants. Gynecologic Oncology, 2000, 79, 90-96.	0.6	34
213	Intraoperative Lymphatic Mapping in Cervix Cancer Patients Undergoing Radical Hysterectomy: A Pilot Study. Gynecologic Oncology, 2000, 79, 238-243.	0.6	146
214	Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma. Journal of Clinical Oncology, 2000, 18, 12-12.	0.8	255
215	Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients. Obstetrics and Gynecology, 2000, 96, 23-27.	1.2	10
216	Phase II Trial of Topotecan in Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 355-357.	0.6	56

#	ARTICLE	IF	CITATIONS
217	Ectopic Production and Localization of β -Human Chorionic Gonadotropin in Lymphoepithelioma-Like Carcinoma of the Cervix: A Case Report. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 179-182.	0.9	11
218	Genetic Changes During the Multistage Pathogenesis of Human Papillomavirus Positive and Negative Vulvar Carcinomas. <i>Journal of the Society for Gynecologic Investigation</i> , 1999, 6, 213-221.	1.9	0
219	Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 365-372.	1.2	12
220	Role of TSG101 in Uterine Cervix Cancer. <i>Gynecologic Oncology</i> , 1999, 75, 401-405.	0.6	6
221	The Ovarian Tumor Index predicts risk for malignancy. , 1999, 86, 2280-2290.		35
222	Abdominal compartment syndrome in gynecologic surgery. <i>Obstetrics and Gynecology</i> , 1999, 94, 830-832.	1.2	7
223	ABDOMINAL COMPARTMENT SYNDROME IN GYNECOLOGIC SURGERY. <i>Obstetrics and Gynecology</i> , 1999, 94, 830-832.	1.2	8
224	Frequent Expression of β -Human Chorionic Gonadotropin (β -hCG) in Squamous Cell Carcinoma of the Cervix. <i>International Journal of Gynecological Pathology</i> , 1999, 18, 381-386.	0.9	32
225	Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. <i>Journal of the Society for Gynecologic Investigation</i> , 1999, 6, 213-221.	1.9	31
226	In Vivo Studies of Adenovirus-Based p53 Gene Therapy for Ovarian Cancer. <i>Gynecologic Oncology</i> , 1998, 69, 197-204.	0.6	31
227	Does Glutamine Supplementation Increase Radioresistance in Squamous Cell Carcinoma of the Cervix?. <i>Gynecologic Oncology</i> , 1998, 71, 359-363.	0.6	9
228	Pathology Slide Review in Gynecologic Oncology. <i>Obstetrics and Gynecology</i> , 1998, 91, 730-734.	1.2	36
229	Abnormalities of Fragile Histidine Triad Genomic and Complementary DNAs in Cervical Cancer: Association With Human Papillomavirus Type. <i>Journal of the National Cancer Institute</i> , 1998, 90, 433-439.	3.0	49
230	Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. <i>Human Molecular Genetics</i> , 1998, 7, 195-202.	1.4	158
231	Pathology Slide Review in Gynecologic Oncology. <i>Obstetrics and Gynecology</i> , 1998, 91, 730-734.	1.2	28
232	Preinvasive and Invasive Breast and Cervical Cancer Prior to or During Pregnancy. <i>Clinics in Perinatology</i> , 1997, 24, 369-389.	0.8	36
233	Long-term results of interstitial implant in locally advanced cervical cancer: A retrospective study of 50 cases. <i>Radiation Oncology Investigations</i> , 1996, 4, 33-40.	1.3	2
234	Immunologic characterization of tumor markers in human ovarian cancer cell lines. <i>Journal of the Society for Gynecologic Investigation</i> , 1996, 3, 216-222.	1.9	16

#	ARTICLE	IF	CITATIONS
235	Adenovirus-Based p53 Gene Therapy in Ovarian Cancer. <i>Gynecologic Oncology</i> , 1995, 59, 171-178.	0.6	73
236	The Effect of Naproxen on Fever in Patients with Advanced Gynecologic Malignancies. <i>Gynecologic Oncology</i> , 1995, 56, 250-254.	0.6	15
237	Transfusion Medicine in Obstetrics and Gynecology. <i>Obstetrical and Gynecological Survey</i> , 1995, 50, 470-481.	0.2	18
238	CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1831-1834.	1.8	91
239	CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1831-1834.	1.8	74
240	DNA Flow Cytometric Analysis of Clinical Stage I Endometrial Carcinomas with Lymph Node Metastases. <i>Gynecologic Oncology</i> , 1993, 50, 20-24.	0.6	23
241	Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. <i>International Journal of Gynecology and Obstetrics</i> , 1993, 42, 94-95.	1.0	12
242	Schistosomiasis and cervical cancer in Ghana. <i>International Journal of Gynecology and Obstetrics</i> , 1993, 42, 127-130.	1.0	16
243	A Phase II Trial of Leuprolide Acetate in Patients with Advanced Epithelial Ovarian Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1992, 15, 125-128.	0.6	33
244	Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. <i>Cancer</i> , 1992, 69, 502-510.	2.0	60
245	Prognostic factors in gestational trophoblastic tumors: A proposed new scoring system based on multivariate analysis. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 611-616.	0.7	76
246	Quantitative protein changes in metastatic versus primary epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 1991, 41, 22-27.	0.6	8
247	Tumor size in endometrial cancer. <i>Cancer</i> , 1991, 67, 2791-2794.	2.0	120
248	Flow cytometric evaluation of epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 162, 1584-1592.	0.7	66
249	Study of the selective cytotoxic properties of cationic, lipophilic mitochondrial-specific compounds in gynecologic malignancies. <i>Gynecologic Oncology</i> , 1990, 39, 72-79.	0.6	41
250	Critical reassessment of second-look laparotomy in epithelial ovarian carcinoma. III. Factors associated with persistent disease-free status and recurrence after "negative" operation. <i>Gynecologic Oncology</i> , 1988, 29, 135.	0.6	0
251	Classification and Staging of Gestational Trophoblastic Tumors. <i>Obstetrics and Gynecology Clinics of North America</i> , 1988, 15, 477-490.	0.7	18
252	Epithelial ovarian carcinoma in patients with intersex disorders: The role of pituitary gonadotropins in ovarian tumorigenesis. <i>Gynecologic Oncology</i> , 1986, 24, 299-308.	0.6	15

#	ARTICLE	IF	CITATIONS
253	A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma. <i>Cancer</i> , 1986, 57, 530-535.	2.0	49
254	Pulsatile Administration of Low-Dose Gonadotropin-Releasing Hormone. Ovulation and Pregnancy in Women with Hypothalamic Amenorrhea. <i>Obstetrical and Gynecological Survey</i> , 1984, 39, 296-297.	0.2	0
255	Pulsatile Administration of Low-Dose Gonadotropin-Releasing Hormone. <i>JAMA - Journal of the American Medical Association</i> , 1983, 250, 2937.	3.8	55
256	Pulsatile administration of low-dose gonadotropin-releasing hormone. Ovulation and pregnancy in women with hypothalamic amenorrhea. <i>JAMA - Journal of the American Medical Association</i> , 1983, 250, 2937-2941.	3.8	21
257	Brief Note: Observations on a Case of Probable Bone Marrow Anthracosis. <i>Blood</i> , 1959, 14, 1350-1353.	0.6	5
258	Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	4